ChoA Pharmaceutical Co., Ltd.
KKRX:0349401,846.00
KRW
-37.00
(-1.96%)
ISIN
KR7034940007
Return %
Stock
S&P 500
1Y
-66.13
14.20
3Y
-81.95
81.12
5Y
-91.16
68.34
Capital Structure
KRW
•
in mil. unless spec.Working Capital
KRW
•
in mil. unless spec.Growth Rates
KRW
•
in mil. unless spec.Quarterly Revenue
KRW
•
in mil. unless spec.Quarterly Earnings Per Share
KRW
•
in mil. unless spec.Quarterly Dividends Per Share
KRW
•
in mil. unless spec.Company Description
- CEO
- Sung-Bae Cho
- Full Time Employees
- 243
- Sector
- Health technology
- Industry
- Pharmaceuticals: other
- Address
- Seoul South Korea
- IPO Date
- Aug 13, 1999
- Website
- choa.co.kr
- Similar Companies
- Business
- ChoA Pharmaceutical Co., Ltd. is a South Korea-based pharmaceutical and healthcare company engaged in the research, development, manufacturing, and distribution of over-the-counter (OTC) drugs, ethical prescription pharmaceuticals, health functional foods, and nutritional supplements. Founded in 1988 and headquartered in Seoul, South Korea, the company operates an advanced Korea Good Manufacturing Practice (KGMP) and ISO 9001-certified manufacturing facility in Haman, Gyeongsangnam-do. ChoA Pharmaceutical is widely recognized for its proprietary oral liquid delivery systems, particularly its patented ChoA Sepage Ampoule double-neck drinkable ampoule packaging technology designed for enhanced safety and stability. The company offers a diversified product portfolio of approximately 200 products across primary therapeutic categories and nutritional segments, including hepatic protectors and liver function restorative treatments, marketed under the flagship Hepos and Hepatos brands; pediatric nutritional and growth support health functional foods, led by the Jalkton series; hematinic and iron deficiency therapeutics, including Fematin; peripheral circulatory and cardiovascular agents, such as Vasoclean; central and peripheral nervous system treatments, including Mabis; multivitamin, tonic, and metabolic formulations, such as Cho-A Bitone; gastrointestinal and digestive remedies; anti-inflammatory, analgesic, and antipyretic medications; respiratory therapies; and functional wellness beverages. ChoA Pharmaceutical manufactures and supplies these products in various dosage forms, including drinkable ampoules, oral liquids, syrups, tablets, capsules, and granules, while also offering custom formulation and contract manufacturing services. ChoA Pharmaceutical distributes its products domestically through an extensive pharmacy network supported by its sister company, MediPharm, which operates one of South Korea's largest pharmacy franchise systems with over 1,200 member locations, as well as through direct supply to hospitals, clinics, and wholesale channels. Geographically, the company exports finished pharmaceuticals and functional health products to international markets across Southeast Asia, including Vietnam and Indonesia, the Middle East, Central Asia, and East Asia. In recent strategic developments, ChoA Pharmaceutical has accelerated its overseas commercial expansion, driving substantial double-digit growth in international export revenue. The company has advanced its retail footprint into Japan through strategic retail partnerships, including supply agreements with the Don Quijote distribution network to roll out flagship brands such as Jalktone and Hepatos Syrup across retail outlets. ChoA Pharmaceutical has also expanded its commercial presence across global pharmaceutical trade platforms, including participation in major international exhibitions such as Arab Health and the World Health Expo in Dubai, while continuously expanding its functional beverage and child nutrition product lines for international distribution.